FDA Drug Establishment Registration: What Foreign Manufacturers Must File

Drug establishment registration is a mandatory legal requirement for every facility that manufactures, prepares, propagates, compounds, or processes drugs for distribution in the United States, including foreign facilities. The requirement derives from Section 510 of the Federal Food, Drug, and Cosmetic Act and is implemented through 21 CFR Part 207. Unlike food facility registration, which uses the FDA's FURLS system, drug establishment registration uses the Drug Registration and Listing System (DRLS). The two systems are entirely separate, and a facility that manufactures both food and drug products — for example, a manufacturer of dietary supplements regulated as conventional food and OTC drug products — must maintain separate registrations in both systems.

Who must register a drug establishment

Any owner or operator of a foreign establishment engaged in the manufacture, preparation, propagation, compounding, or processing of a drug product that is imported or offered for import into the United States must register. The definition of manufacture is broad: it includes synthesis, extraction, formulation, mixing, packaging, repackaging, labeling, and relabeling. Contract manufacturers that produce finished dose forms, active pharmaceutical ingredient (API) manufacturers, and repackagers of imported drug products are all covered. Importers who do not physically manufacture drugs are not required to register as drug establishments, but every facility in the manufacturing supply chain that touches the drug product is.

What the registration covers and what it requires

The drug establishment registration must include the facility's legal name and address, the name and address of the US Agent, the type of establishment (manufacturer, repacker, relabeler, API manufacturer, etc.), and a list of the drug products or drug categories manufactured at that facility. Drug listing — a separate but related obligation under Section 510(j) — requires the registered establishment to list each drug product it manufactures, including the NDC number, the proprietary and non-proprietary name, active and inactive ingredients, dosage form, route of administration, and whether the product is prescription or OTC. Drug listing must be submitted simultaneously with or following establishment registration; a facility cannot list products without first being registered.

The annual re-registration window and why it matters

Drug establishment registrations must be renewed annually during the October 1 through December 31 window. This is unlike food facility registration, which must be renewed every two years during the same October–December period. Missing the annual drug establishment re-registration window means the registration lapses, and a lapsed registration means the facility's drug products cannot legally be imported into the United States. The FDA sends no advance reminder notices. The responsibility for tracking the re-registration deadline rests entirely with the registrant — which in practice means the registered facility's US Agent, since that is who receives FDA correspondence.

Foreign drug establishments versus domestic — what differs

Domestic drug establishments and foreign drug establishments face the same substantive registration requirements but differ in one important structural element: foreign establishments must designate a US Agent at the time of registration. The US Agent must be physically located in the United States, must be available to the FDA at all times, and must be prepared to assist with inspections, respond to correspondence, and relay compliance information between the FDA and the foreign facility in real time. Foreign drug establishment registrations that list a US Agent who is unavailable, unreachable, or unfamiliar with the facility's operations create a practical gap in the regulatory relationship that the FDA has statutory authority to act on.

How FDABridge handles drug establishment registration

FDABridge manages drug establishment registration, drug listing, annual re-registration, and US Agent appointment for foreign drug manufacturers. Our system tracks every filing deadline and contacts clients well in advance of the annual October re-registration window. Visit fdabridge.com/drug to learn about our drug registration services or fdabridge.com/apply/drug to start the filing process.